Bleeding pattern and management of unexpected bleeding/spotting with an extended regimen of a combination of ethinylestradiol 20 mcg and drospirenone 3 mg

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorJundiaí School of Medicine-
Autor(es): dc.contributorABC School of Medicine-
Autor(es): dc.contributorFederal University of Parana-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorFederal University of Rio Grande do Sul-
Autor(es): dc.contributorLibbs Farmacêutica Ltda-
Autor(es): dc.creatorMachado, Rogerio Bonassi-
Autor(es): dc.creatorPompei, Luciano De Melo-
Autor(es): dc.creatorAndrade, Rosires-
Autor(es): dc.creatorNahas, Eliana [UNESP]-
Autor(es): dc.creatorGuazzelli, Cristina-
Autor(es): dc.creatorWender, Maria Celeste-
Autor(es): dc.creatorCruz, Achilles Machado-
Data de aceite: dc.date.accessioned2022-02-22T00:30:17Z-
Data de disponibilização: dc.date.available2022-02-22T00:30:17Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2019-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.2147/IJWH.S238294-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/200341-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/200341-
Descrição: dc.descriptionObjective: To compare the bleeding pattern in women using ethinylestradiol 20 mcg/ drospirenone 3 mg (EE 20 mcg/DRSP 3 mg) in a 24/4-day cyclic regimen with an extended regimen. Unexpected bleeding/spotting in the extended regimen group was managed by allowing a 4-day hormone-free interval (HFI). Methods: This was a randomized, prospective, open-label, multicenter study. Participants (N = 348) were randomized to receive EE 20 mcg/DRSP 3 mg in either an extended regimen (EE/DRSPes group) or a 24/4-day cyclic regimen (EE/DRSP24/4 group) and followed for 168 days. In the EE/DRSPes group, a 4-day HFI was allowed whenever unexpected bleeding/ spotting persisted for ≥7 consecutive days. The participants assessed their bleeding daily as “no bleeding,” “spotting,” or “light,” “moderate,” or “heavy” bleeding according to a predefined scale. Results: EE/DRSPes group experienced fewer days of bleeding than those using a 24/4 cyclic regimen (P < 0.001). After 168 days, 57.5% of women in the EE/DRSPes group achieved complete amenorrhea (i.e., neither bleeding nor spotting) and 73.9% achieved “no bleeding” (i.e., no bleeding with or without spotting) during the final 28-day interval of the study period. Women in the extended group who instituted the 4-day HFI experienced a 94.1% rate of successful management of unexpected bleeding/spotting. Conclusion: The use of EE 20 mcg/DRSP 3 mg in an extended regimen resulted in high rates of amenorrhea and “no bleeding”. Unexpected bleeding/spotting in the EE/DRSPes group could be managed effectively with a 4-day HFI. Clinical Trial Registration: International Standard Randomised Controlled Trial Number (ISRCTN57661673): http://www.controlled-trials.com/isrctn/pf/57661673.-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Jundiaí School of Medicine-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics ABC School of Medicine-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Federal University of Parana-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Botucatu Medical School (Unesp)-
Descrição: dc.descriptionDepartment of Obstetrics Federal University of Sao Paulo-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Federal University of Rio Grande do Sul-
Descrição: dc.descriptionDepartment of Clinical Research Libbs Farmacêutica Ltda-
Descrição: dc.descriptionDepartment of Gynecology and Obstetrics Botucatu Medical School (Unesp)-
Formato: dc.format235-242-
Idioma: dc.languageen-
Relação: dc.relationInternational Journal of Women's Health-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBleeding profile-
Palavras-chave: dc.subjectCombined oral contraceptives-
Palavras-chave: dc.subjectDrospirenone-
Palavras-chave: dc.subjectExtended regimen-
Palavras-chave: dc.subjectLow dose oral contraceptive-
Título: dc.titleBleeding pattern and management of unexpected bleeding/spotting with an extended regimen of a combination of ethinylestradiol 20 mcg and drospirenone 3 mg-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.